Northern Trust’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.7M | Sell |
1,945,586
-367,647
| -16% | -$505K | ﹤0.01% | 2810 |
|
|
2025
Q4 | $3.72M | Sell |
2,313,233
-173,302
| -7% | -$363K | ﹤0.01% | 2646 |
|
|
2025
Q3 | $6.79M | Buy |
2,486,535
+351,291
| +16% | +$1.17M | ﹤0.01% | 2324 |
|
|
2025
Q2 | $7.77M | Buy |
2,135,244
+424,053
| +25% | +$1.17M | ﹤0.01% | 2211 |
|
|
2025
Q1 | $3.29M | Buy |
1,711,191
+25,550
| +2% | +$52.2K | ﹤0.01% | 2644 |
|
|
2024
Q4 | $3.2M | Buy |
1,685,641
+50,542
| +3% | +$87.8K | ﹤0.01% | 2770 |
|
|
2024
Q3 | $2.16M | Buy |
1,635,099
+1,198,213
| +274% | +$1.6M | ﹤0.01% | 2953 |
|
|
2024
Q2 | $446K | Buy |
436,886
+102,713
| +31% | +$127K | ﹤0.01% | 3549 |
|
|
2024
Q1 | $612K | Buy |
334,173
+23,805
| +8% | +$38.1K | ﹤0.01% | 3492 |
|
|
2023
Q4 | $385K | Buy |
310,368
+8,247
| +3% | +$8.41K | ﹤0.01% | 3633 |
|
|
2023
Q3 | $344K | Sell |
302,121
-18,837
| -6% | -$24.2K | ﹤0.01% | 3618 |
|
|
2023
Q2 | $294K | Sell |
320,958
-51,500
| -14% | -$49.7K | ﹤0.01% | 3680 |
|
|
2023
Q1 | $209K | Buy |
372,458
+13,348
| +4% | +$10.2K | ﹤0.01% | 3845 |
|
|
2022
Q4 | $207K | Sell |
359,110
-1,235
| -0.3% | -$387 | ﹤0.01% | 3856 |
|
|
2022
Q3 | $114K | Sell |
360,345
-181
| -0.1% | -$71 | ﹤0.01% | 4071 |
|
|
2022
Q2 | $127K | Sell |
360,526
-1,315,595
| -78% | -$552K | ﹤0.01% | 4082 |
|
|
2022
Q1 | $1.2M | Sell |
1,676,121
-69,933
| -4% | -$150K | ﹤0.01% | 3346 |
|
|
2021
Q4 | $3.95M | Sell |
1,746,054
-26,117
| -1% | -$71.2K | ﹤0.01% | 2833 |
|
|
2021
Q3 | $5.1M | Buy |
1,772,171
+81,363
| +5% | +$232K | ﹤0.01% | 2716 |
|
|
2021
Q2 | $6.41M | Buy |
1,690,808
+34,569
| +2% | +$116K | ﹤0.01% | 2691 |
|
|
2021
Q1 | $5.61M | Sell |
1,656,239
-91,372
| -5% | -$329K | ﹤0.01% | 2676 |
|
|
2020
Q4 | $4.89M | Sell |
1,747,611
-44,081
| -2% | -$129K | ﹤0.01% | 2696 |
|
|
2020
Q3 | $4.5M | Buy |
1,791,692
+17,977
| +1% | +$158K | ﹤0.01% | 2606 |
|
|
2020
Q2 | $24.1M | Buy |
1,773,715
+305,838
| +21% | +$3.16M | 0.01% | 1462 |
|
|
2020
Q1 | $11.1M | Sell |
1,467,877
-4,117
| -0.3% | -$32K | ﹤0.01% | 1807 |
|
|
2019
Q4 | $9.3M | Buy |
1,471,994
+37,154
| +3% | +$177K | ﹤0.01% | 2223 |
|
|
2019
Q3 | $5.62M | Buy |
1,434,840
+282,258
| +24% | +$1.21M | ﹤0.01% | 2483 |
|
|
2019
Q2 | $5.58M | Buy |
1,152,582
+31,036
| +3% | +$177K | ﹤0.01% | 2502 |
|
|
2019
Q1 | $9.19M | Buy |
1,121,546
+56,165
| +5% | +$385K | ﹤0.01% | 2206 |
|
|
2018
Q4 | $5.89M | Buy |
1,065,381
+430,985
| +68% | +$3.37M | ﹤0.01% | 2402 |
|
|
2018
Q3 | $5.6M | Buy |
634,396
+21,209
| +3% | +$190K | ﹤0.01% | 2620 |
|
|
2018
Q2 | $6.12M | Buy |
613,187
+94,348
| +18% | +$945K | ﹤0.01% | 2578 |
|
|
2018
Q1 | $4.94M | Buy |
518,839
+5,383
| +1% | +$75.3K | ﹤0.01% | 2603 |
|
|
2017
Q4 | $7.63M | Sell |
513,456
-1,699
| -0.3% | -$28.2K | ﹤0.01% | 2357 |
|
|
2017
Q3 | $10.1M | Buy |
515,155
+91,062
| +21% | +$1.4M | ﹤0.01% | 2201 |
|
|
2017
Q2 | $6.09M | Buy |
424,093
+55,763
| +15% | +$707K | ﹤0.01% | 2495 |
|
|
2017
Q1 | $3.39M | Buy |
368,330
+2,680
| +0.7% | +$26.2K | ﹤0.01% | 2795 |
|
|
2016
Q4 | $3.81M | Sell |
365,650
-11,728
| -3% | -$101K | ﹤0.01% | 2722 |
|
|
2016
Q3 | $3.42M | Buy |
377,378
+6,274
| +2% | +$53.3K | ﹤0.01% | 2775 |
|
|
2016
Q2 | $2.78M | Buy |
371,104
+54,955
| +17% | +$480K | ﹤0.01% | 2852 |
|
|
2016
Q1 | $2.85M | Buy |
316,149
+77,762
| +33% | +$631K | ﹤0.01% | 2778 |
|
|
2015
Q4 | $3.08M | Buy |
238,387
+5,145
| +2% | +$52.5K | ﹤0.01% | 2781 |
|
|
2015
Q3 | $2.25M | Buy |
233,242
+101,602
| +77% | +$932K | ﹤0.01% | 2981 |
|
|
2015
Q2 | $1.35M | Buy |
131,640
+50,756
| +63% | +$433K | ﹤0.01% | 3228 |
|
|
2015
Q1 | $899K | Buy |
80,884
+781
| +1% | +$8.31K | ﹤0.01% | 3436 |
|
|
2014
Q4 | $932K | Buy |
80,103
+685
| +0.9% | +$9.82K | ﹤0.01% | 3403 |
|
|
2014
Q3 | $1.76M | Buy |
79,418
+58,657
| +283% | +$1.35M | ﹤0.01% | 3183 |
|
|
2014
Q2 | $577K | Buy |
+20,761
| New | +$500K | ﹤0.01% | 3559 |
|
Other funds holding AKBA
VCM
VPM
Northern Trust's AKBA Position: Q1 2026 in Review
Northern Trust reduced its Akebia Therapeutics (AKBA) stake by 16% in Q1 2026, selling an estimated $505K and leaving 1,945,586 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2810.
Northern Trust first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $24.1M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Northern Trust held 1,945,586 shares of Akebia Therapeutics worth $2.7M as of Q1 2026.
- Northern Trust sold 367,647 Akebia Therapeutics shares in Q1 2026, an estimated $505K.
- Akebia Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2810 holding.
- Northern Trust first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
- Northern Trust's Akebia Therapeutics position peaked at $24.1M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.